PD-1/PDL-1 immunoinhibitory pathway: Higher expression of PDL-1 in patients with enzalutamide-resistant PCa prompted the phase III IMbassador250 trial that combined enzalutamide with the PDL-1 blocker atezolizumab in mCRPC after progression on abiraterone or chemotherapy [142]. The gene discussed is CD274; the disease is posterior cortical atrophy.